VU 0409106

Discontinued Product

VU 0409106 (Cat. No. 5322) has been withdrawn from sale for commercial reasons.
Description: Potent and selective negative allosteric modulator of mGlu5 receptors
Chemical Name: 3-Fluoro-N-(4-methyl-2-thiazolyl)-5-(5-pyrimidinyloxy)benzamide
Purity: ≥98% (HPLC)
Literature (5)

Biological Activity for VU 0409106

VU 0409106 is a potent and selective mGlu5 negative allosteric modulator (IC50 = 49 nM at human mGlu5). Selective for mGlu5 over a panel of GPCRs and ion channels. Exhibits no significant nonspecific binding in rat brain homogenates in vitro. Inhibits marble burying behavior in mice. Brain penetrant.

Compound Libraries for VU 0409106

VU 0409106 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for VU 0409106

M. Wt 330.34
Formula C15H11FN4O2S
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 1276617-62-9
PubChem ID 50990953
Smiles FC1=CC(OC2=CN=CN=C2)=CC(C(NC3=NC(C)=CS3)=O)=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for VU 0409106

References are publications that support the biological activity of the product.

Felts et al (2013) Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bioorg.Med.Chem.Lett. 23 5779 PMID: 24074843

View Related Products by Product Action

View all Glutamate (Metabotropic) Group I Receptor Modulators

Keywords: VU 0409106, VU 0409106 supplier, VU0409106, metabotropic, glutamate, receptors, negative, allosteric, modulators, NAMs, mGluR5, class, I, Glutamate, (Metabotropic), Group, Receptors, 5322, Tocris Bioscience

Citations for VU 0409106

Citations are publications that use Tocris products.

Currently there are no citations for VU 0409106.

Reviews for VU 0409106

There are currently no reviews for this product. Be the first to review VU 0409106 and earn rewards!

Have you used VU 0409106?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.